Drug Patents owned by Kyowa Kirin

1. Drug name - NOURIANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(2 years from now)

CN1784405A KYOWA KIRIN Microcrystalline
May, 2024

(1 year, 7 months from now)

CN100395245C KYOWA KIRIN Microcrystalline
May, 2024

(1 year, 7 months from now)

EP1626049A1 KYOWA KIRIN Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione
May, 2024

(1 year, 7 months from now)

EP1626049B1 KYOWA KIRIN Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione
May, 2024

(1 year, 7 months from now)

EP1626049A4 KYOWA KIRIN Microcrystal
May, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders Jan, 2023

(3 months from now)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy Jan, 2023

(4 months from now)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound Sep, 2027

(4 years from now)

Drugs and Companies using ISTRADEFYLLINE ingredient

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

2. Drug name - SANCUSO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7608282 KYOWA KIRIN Transdermal granisetron Jan, 2025

(2 years from now)

Drugs and Companies using GRANISETRON ingredient

Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
3.1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.